Accolade (ACCD) Stock Forecast, Price & News

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accolade in the last twelve months. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ACCD shares.
View ACCD analyst ratings or view top-rated stocks.

15 Wall Street analysts have issued 12-month price targets for Accolade's shares. Their ACCD share price forecasts range from $13.00 to $19.00. On average, they anticipate the company's stock price to reach $15.59 in the next year. This suggests a possible upside of 44.9% from the stock's current price.
View analysts price targets for ACCD or view top-rated stocks among Wall Street analysts.

Accolade's stock was trading at $7.79 at the start of the year. Since then, ACCD stock has increased by 38.1% and is now trading at $10.76.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 4th 2023.
View our ACCD earnings forecast.

Accolade will be holding an earnings conference call on Wednesday, October 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Accolade, Inc. (NASDAQ:ACCD) announced its quarterly earnings results on Thursday, June, 29th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.10. The business earned $93.20 million during the quarter, compared to the consensus estimate of $90.82 million. Accolade had a negative trailing twelve-month return on equity of 32.34% and a negative net margin of 41.86%. The firm's revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.62) EPS.

ETFs with the largest weight of Accolade (NASDAQ:ACCD) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), SPDR S&P Health Care Services ETF (XHS), Invesco Dorsey Wright Healthcare Momentum ETF (PTH) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF).

Accolade issued an update on its second quarter earnings guidance on Wednesday, July, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $93.00 million-$95.00 million, compared to the consensus revenue estimate of $93.22 million.

152 employees have rated Accolade Chief Executive Officer Rajeev Singh on Glassdoor.com. Rajeev Singh has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Accolade investors own include CVS Health (CVS), Johnson & Johnson (JNJ), RTX (RTX), Alibaba Group (BABA), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Intel (INTC).

(ACCD) raised $176 million in an initial public offering on Thursday, July 2nd 2020. The company issued 8,800,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs, Morgan Stanley and BofA Securities served as the underwriters for the IPO and Piper Sandler, Credit Suisse, William Blair, Baird and SVB Leerink were co-managers.

Accolade trades on the NASDAQ under the ticker symbol "ACCD."

Accolade's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (8.72%), Brown Advisory Inc. (8.06%), ARK Investment Management LLC (7.52%), Bellevue Group AG (5.98%), Rock Springs Capital Management LP (3.73%) and Dimensional Fund Advisors LP (2.05%). Insiders that own company stock include Colin Mchugh, Michael W Hilton, Rajeev Singh, Richard Eskew, Robert N Cavanaugh, Stephen H Barnes and Thomas J Neff.
View institutional ownership trends.

Shares of ACCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACCD stock can currently be purchased for approximately $10.76.

Accolade (NASDAQ:ACCD) has a market capitalization of $813.78 million and generates $363.14 million in revenue each year. The company earns $-459,650,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis.

The company employs 2,370 workers across the globe.

Accolade's mailing address is 660 W. GERMANTOWN PIKE SUITE 500, PLYMOUTH MEETING PA, 19462. The official website for the company is accolade.com. The company can be reached via phone at 206-926-8100 or via email at ir@accolade.com.